Market Cap: $196.23M
NI
Niagen Bioscience Inc
NAGE
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $196.23M
Niagen Bioscience (Ticker: NAGE) enhances its commitment to scientific innovation through a comprehensive rebranding initiative. The company transitions from the ChromaDex External Research Program to…
Niagen Bioscience Sets Ambitious Growth Plans Following Record Financial Success Niagen Bioscience (NASDAQ:NAGE), a frontrunner in the anti-aging product market, announces its most impressive financia…
Niagen Bioscience on the Cutting Edge of Anti-Aging Innovation Niagen Bioscience positions itself as a leading player in the burgeoning anti-aging market, recently reporting a landmark achievement wit…
Avaí Bio's Strategic Advancements in Anti-Aging Therapies Avaí Bio, Inc., a trailblazer in the biotechnology sector focused on anti-aging therapies, has embarked on a significant initiative by launchi…
Niagen Bioscience: Pioneering Developments in Cellular Health Niagen Bioscience stands at the forefront of biotechnology with its innovative approach to enhancing cellular health through nicotinamide…
Niagen Bioscience: A Focus on Revenue Growth Amid Industry Developments Niagen Bioscience continues to make strides in the biotechnology sector, emphasizing its commitment to developing innovative sol…
### Niagen Bioscience: Strategic Growth and Market Positioning Ahead of Earnings Announcement Niagen Bioscience is poised to release its quarterly earnings on August 6, 2025, a pivotal moment for the…
Niagen Bioscience Prepares for Significant Earnings Announcement As Niagen Bioscience (NAGE) approaches its quarterly earnings announcement on August 6, 2025, the company attracts significant attentio…
### Niagen Bioscience's Strategic Leadership Moves Signal Confidence in Growth Niagen Bioscience (NAGE) experiences a noteworthy development as Wendy Tak Wing YU, the company's Director, exercises a s…
Niagen Bioscience Director Exercises Stock Options, Signaling Confidence in Future Prospects On June 26, Niagen Bioscience (NAGE) announces a substantial exercise of stock options by its Director, Ste…
Insider Confidence Boosts Niagen Bioscience's Strategic Outlook Niagen Bioscience (NAGE) recently highlights a significant development in its corporate governance through substantial stock option exer…
Niagen Bioscience Leadership Actions Signal Confidence in Future Growth On June 26, Niagen Bioscience (NAGE) reveals in an SEC filing that its Director, Steven Rubin, has executed a significant stock…